IRS2 expression was lower in MDS patients with ≥5% bone marrow blasts than in MDS patients with <5% bone marrow blasts, and IRS2 downregulation was associated with an increased severity of cytopenia 40. This evidence concerns the gene IRS2 and myelodysplastic syndrome.